Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience

Arslan, Uğur; YENERÇAĞ, Mustafa; KUL, Selim; ATEŞ, AHMET HAKAN; ÖZBALCI, Aysu Başak; Okşul, Metin

Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience

Ahmet Hakan ATEŞ, (Hacettepe Üniversitesi)

Aysu Başak ÖZBALCI, (Sağlık Bilimleri Üniversitesi Samsun Eğitim ve Araştırma Hastanesi)

Selim KUL, (Sağlık Bilimleri Üniversitesi Ahi Evran Eğitim ve Araştırma Hastanesi)

Mustafa YENERÇAĞ, (Sağlık Bilimleri Üniversitesi)

Metin OKŞUL, (Hacettepe Üniversitesi)

Uğur ARSLAN (Sağlık Bilimleri Üniversitesi)

Acta Medica

7 2

Yıl: 2019 Cilt: 50 Sayı: 4 Sayfa Aralığı: 30 - 35 Metin Dili: İngilizce İndeks Tarihi: 26-03-2020

Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience

Öz:

Objectives: Superficial femoral artery is the most commonly effected vessel in peripheral arterial disease and superficial femoral artery total occlusions constitute the 50%of peripheral arterial disease patients presenting with symptoms. In this study, we investigated our patients with superficial femoral artery total occlusions who were treated with percutaneous treatment strategy.Materials and Methods: In this study, we included ambulatory patients who were admitted to our clinics due to symptomatic severe superficial femoral artery total occlusion and underwent percutaneous transluminal angioplasty or underwent percutaneous transluminal angioplasty + stenting procedure. The demographic findings of thepatients, procedure details, complications and follow-up results were noted.Results: Out of 67 patients, 62 (92.5%) underwent percutaneous transluminal angioplasty or percutaneous transluminal angioplasty + stenting procedure successfully forsuperficial femoral artery total occlusions. Only one serious complication, acute renalfailure resulting in death developed during hospitalization. The mean follow-up timeafter the procedure was 11.1±7.2 months. During this follow-up time 36 (58.1%) wereasymptomatic. Out of 26 patients who were symptomatic, only 6 of them underwentreintervention and 3 were recommended surgical intervention.Conclusion: Peripheral interventions for superficial femoral artery total occlusions arebeing performed successfully in experienced centers with low complication rates asthe first treatment strategy in peripheral arterial disease. Herein, we have presentedour patients who underwent successful percutaneous transluminal angioplasty and/orstenting procedure with high success and low complication rates. Peripheral interventions should be the first choice for superficial femoral artery superficial femoral arterytotal occlusions in experienced centers.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

[1] Shah AM, Banerjee T, Mukherjee D. Coronary, peripheral and cerebrovascular disease: a complex relationship. Journal of the Indian Medical Association 2010; 108: 292-96.
[2] Tadros RO, Vouyouka AG, Ting W, et al. A Review of Superficial Femoral Artery Angioplasty and Stenting. J Vasc Med Surg 2015;3:1-5.
[3] Nadal LL, Cynamon J, Lipsitz EC, et al. Subintimal angioplasty for chronic arterial occlusions. Tech Vasc Interv Radiol 2004; 7,16-22.
[4] Dotter C.T, Judkins MP. Transluminal Treatment of Arteriosclerotic Obstruction. Description of A New Technic and A Preliminary Report of Its Application. Circulation 1964; 30:654-70.
[5] Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group: Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45, S5–S67.
[6] Setacci C, de Donato G, Teraa M, et al. Chapter IV: treatment of critical limb ischaemia [Review]. Eur J Vasc Endovasc Surg 42: S43-59.
[7] Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33:S1-75.
[8] Carman T, Fernandez BB Jr. A primary care approach to the patient with claudication. Am Fam Physician 2000; 61:1027-34.
[9] Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106:1505-9.
[10] Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16:331-8.
[11] Marie D, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 69:1465-1508.
[12] Baum S, Pentecost MD. Abram’s Angiography. Interventional Radiology. 2nd Ed. Philedelphia: Lipincott Williams & Wilkins.2006; 329-47.
[13] Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. Circulation 1994; 89:511-31.
[14] Valji K. Vascular and Interventional Radiology. 2nd Ed. Philedelphia: Elsevier. 2006; 34-36.
[15] Kawarada O, Higashimori A, Noguchi M, et al. Duplex criteria for instent restenosis in the superficial femoral artery. Catheter Cardiovasc Interv 2013; 281, E199-205.
[16] Itoga NK, Kim T, Sailer AM, et al, Lower extremity computed tomography angiography can help predict technical success of endovascular revascularization in the superficial femoral and popliteal artery. J Vasc Surg. 2017; 11, S0741-0748.

APA	ATEŞ A, ÖZBALCI A, KUL S, YENERÇAĞ M, Okşul M, Arslan U (2019). Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. , 30 - 35.
Chicago	ATEŞ AHMET HAKAN,ÖZBALCI Aysu Başak,KUL Selim,YENERÇAĞ Mustafa,Okşul Metin,Arslan Uğur Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. (2019): 30 - 35.
MLA	ATEŞ AHMET HAKAN,ÖZBALCI Aysu Başak,KUL Selim,YENERÇAĞ Mustafa,Okşul Metin,Arslan Uğur Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. , 2019, ss.30 - 35.
AMA	ATEŞ A,ÖZBALCI A,KUL S,YENERÇAĞ M,Okşul M,Arslan U Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. . 2019; 30 - 35.
Vancouver	ATEŞ A,ÖZBALCI A,KUL S,YENERÇAĞ M,Okşul M,Arslan U Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. . 2019; 30 - 35.
IEEE	ATEŞ A,ÖZBALCI A,KUL S,YENERÇAĞ M,Okşul M,Arslan U "Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience." , ss.30 - 35, 2019.
ISNAD	ATEŞ, AHMET HAKAN vd. "Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience". (2019), 30-35.

APA	ATEŞ A, ÖZBALCI A, KUL S, YENERÇAĞ M, Okşul M, Arslan U (2019). Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. Acta Medica, 50(4), 30 - 35.
Chicago	ATEŞ AHMET HAKAN,ÖZBALCI Aysu Başak,KUL Selim,YENERÇAĞ Mustafa,Okşul Metin,Arslan Uğur Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. Acta Medica 50, no.4 (2019): 30 - 35.
MLA	ATEŞ AHMET HAKAN,ÖZBALCI Aysu Başak,KUL Selim,YENERÇAĞ Mustafa,Okşul Metin,Arslan Uğur Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. Acta Medica, vol.50, no.4, 2019, ss.30 - 35.
AMA	ATEŞ A,ÖZBALCI A,KUL S,YENERÇAĞ M,Okşul M,Arslan U Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. Acta Medica. 2019; 50(4): 30 - 35.
Vancouver	ATEŞ A,ÖZBALCI A,KUL S,YENERÇAĞ M,Okşul M,Arslan U Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience. Acta Medica. 2019; 50(4): 30 - 35.
IEEE	ATEŞ A,ÖZBALCI A,KUL S,YENERÇAĞ M,Okşul M,Arslan U "Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience." Acta Medica, 50, ss.30 - 35, 2019.
ISNAD	ATEŞ, AHMET HAKAN vd. "Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience". Acta Medica 50/4 (2019), 30-35.